Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excedrin Extra Strength OTC indication for migraine pain supported by studies -- Bristol.

This article was originally published in The Tan Sheet

Executive Summary

EXCEDRIN EXTRA STRENGTH OTC INDICATION FOR MIGRAINE PAIN is supported by three clinical trials involving subjects with migraine, according to Bristol-Myers Squibb. Results of the trials, which include comparisons of Excedrin Extra Strength to placebo and to prescription migraine drugs, will be presented by the company at the July 15 joint meeting of FDA's Nonprescription Drugs and Arthritis Advisory Committees ("The Tan Sheet" June 2, p. 3). Representatives from the agency's Peripheral & Central Nervous System Advisory Committee also will attend.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel